Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2 inhibitor type, placebo-controlled trial, - a Phase III study. Primary objective of the study is to investigate the impact of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on clinical endpoints in patients hospitalized with acute/decompensated HF.
Epistemonikos ID: c70e4cb1369ec46bf4bca1bdeb313deba1c66694
First added on: Feb 19, 2024